Magdalena Zalacain
Labege, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).
Journal: Antimicrobial agents and chemotherapy
Published: February 19, 2026
Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii.
Journal: Antimicrobial agents and chemotherapy
Published: January 30, 2024
Higher levels of Pseudomonas aeruginosa LasB elastase expression are associated with early-stage infection in cystic fibrosis patients.
Journal: Scientific reports
Published: February 28, 2023
Chemical Optimization of Selective Pseudomonas aeruginosa LasB Elastase Inhibitors and Their Impact on LasB-Mediated Activation of IL-1β in Cellular and Animal Infection Models.
Journal: ACS infectious diseases
Published: January 20, 2023
Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales.
Journal: Antimicrobial agents and chemotherapy
Published: February 06, 2021
Discovery of ANT3310, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii.
Journal: Journal of medicinal chemistry
Published: December 11, 2020
Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models".
Journal: Antimicrobial agents and chemotherapy
Published: November 24, 2020
Pseudomonas aeruginosa Elastase Contributes to the Establishment of Chronic Lung Colonization and Modulates the Immune Response in a Murine Model.
Journal: Frontiers in microbiology
Published: October 23, 2020
ANT2681: SAR Studies Leading to the Identification of a Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.
Journal: ACS infectious diseases
Published: August 14, 2020
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.
Journal: Antimicrobial agents and chemotherapy
Published: May 27, 2020
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model.
Journal: ACS infectious diseases
Published: November 15, 2018
Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.
Journal: Antimicrobial agents and chemotherapy
Published: January 16, 2018
Last Updated: 09/26/2026